Akèy › Lukemi lenfositè kwonik › North Carolina › Durham
Etid klinik pou Lukemi lenfositè kwonik nan Durham, NC
27 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Ap rekriteFaz 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Durham VA Medical Center, Durham
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Ap rekriteFaz 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
- University of North Carolina-Hillsborough Campus, Hillsborough · 13 mi lwen
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
- University of North Carolina At Chapel Hill, Chapel Hill · 10 mi lwen
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Ap rekriteFaz 3
- Duke University Medical Center, Durham
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 3
- Duke University Medical Center, Durham
- University of North Carolina At Chapel Hill, Chapel Hill · 10 mi lwen
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- Duke University, Durham
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
- Duke University, Durham
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Ap rekriteFaz 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10 mi lwen
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi lwen
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Ap rekriteFaz 2
- Research Site, Durham
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Ap rekriteFaz 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Duke University Medical Center, Durham
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Ap rekrite
- North Carolina Basnight Cancer Hospital, Chapel Hill · 10 mi lwen
Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Ap rekriteFaz 4
- Duke University Medical Center, Durham
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Ap rekriteFaz 4
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- Duke University, Durham
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 2
- University of North Carolina /ID# 233313, Chapel Hill · 10 mi lwen
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Ap rekriteFaz 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Ap rekriteFaz 2
- Durham VA Medical Center, Durham, NC, Durham
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Ap rekriteFaz 1
- Duke University, Durham
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Chicago, IL14 etid
- Cincinnati, OH14 etid
- Nashville, TN13 etid
Lòt etid nan Durham
- Kansè nan tete63 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Kansè Metastatik33 etid
- Leksemi mieloïd egi33 etid
- Kansè poumon32 etid
- Kansè pwostat32 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Ensifizyans kadyak26 etid
- Kansè pankreyas24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.